Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Autor: Butowski, Nicholas, Campian, Jian, Recht, Lawrence, Lim, Michael, Ashby, Lynn, Drappatz, Jan, Hirte, Hal, Iwamoto, Fabio, Mechtler, Laszlo, Goldlust, Samuel, Becker, Kevin, Barnett, Gene, Nicholas, Garth, Desjardins, Annick, Benkers, Tara, Wagle, Naveed, Groves, Morris, Kesari, Santosh, Horvath, Zsolt, Merrell, Ryan, Curry, Richard, O'Rourke, James, Schuster, David, Wong, Mark, Mrugala, Maciej, Jensen, Randy, Trusheim, John, Lesser, Glenn, Belanger, Karl, Sloan, Andrew, Purow, Benjamin, Fink, Karen, Raizer, Jeffrey, Schulder, Michael, Nair, Suresh, Peak, Scott, Perry, James, Brandes, Alba, Weller, Michael, Mohile, Nimish, Landolfi, Joseph, Olson, Jon, Finocchiaro, Gaetano, Jennens, Ross, DeSouza, Paul, Robinson, Bridget, Crittenden, Marka, Shih, Kent, Flowers, Alexandra, Ong, Shirley, Connelly, Jennifer, Hadjipanayis, Costas, Giglio, Pierre, Mott, Frank, Mathieu, David, Lessard, Nathalie, Sepulveda, Sanchez Juan, Lövey, József, Wheeler, Helen, Inglis, Po-Ling, Hardie, Claire, Bota, Daniela, Lesniak, Maciej, Portnow, Jana, Frankel, Bruce, Junck, Larry, Thompson, Reid, Berk, Lawrence, McGhie, John, Macdonald, David, Saran, Frank, Soffietti, Riccardo, Blumenthal, Deborah, André de, Sá Barreto Costa Marcos, Nowak, Anna, Singhal, Nimit, Hottinger, Andreas, Schmid, Andrea, Srkalovic, Gordan, Baskin, David, Fadul, Camilo, Nabors, Louis, LaRocca, Renato, Villano, John, Paleologos, Nina, Kavan, Petr, Pitz, Marshall, Thiessen, Brian, Idbaih, Ahmed, Frenel, Jean Sébastien, Domont, Julien, Grauer, Oliver, Hau, Peter, Marosi, Christine, Sroubek, Jan, Hovey, Elizabeth, Sridhar, P.S., Cher, Lawrence, Dunbar, Erin, Coyle, Thomas, Raymond, Jane, Barton, Kevin, Guarino, Michael, Raval, Sumul, Stea, Baldassarre, Dietrich, Jorge, Hopkins, Kirsten, Erridge, Sara, Steinbach, Joachim-Peter, Pineda, Losada Estela, Balana, Quintero Carmen, Sonia del, Barco Berron, Wenczl, Miklós, Molnár, Katalin, Hideghéty, Katalin, Lossos, Alexander, Myra van, Linde, Levy, Ana, Harrup, Rosemary, Patterson, William, Lwin, Zarnie, Sathornsumetee, Sith, Lee, E-Jian, Ho, Jih-Tsun, Emmons, Steven, Duic, J. Paul, Shao, Spencer, Ashamalla, Hani, Weaver, Michael, Lutzky, Jose, Avgeropoulos, Nicholas, Hanna, Wahid, Nadipuram, Mukund, Cecchi, Gary, O'Donnell, Robert, Pannullo, Susan, Carney, Jennifer, Hamilton, Mark, MacNeil, Mary, Beaney, Ronald, Fabbro, Michel, Schnell, Oliver, Fietkau, Rainer, Stockhammer, Guenther, Malinova, Bela, Odrazka, Karel, Sames, Martin, Miguel Gil, Gil, Razis, Evangelia, Lavrenkov, Konstantin, Castro, Guillermo, Ramirez, Francisco, Baldotto, Clarissa, Viola, Fabiana, Malheiros, Suzana, Lickliter, Jason, Gauden, Stanislaw, Dechaphunkul, Arunee, Thaipisuttikul, Iyavut, Thotathil, Ziad, Ma, Hsin-I, Cheng, Wen-Yu, Chang, Chin-Hong, Salas, Fernando, Dietrich, Pierre-Yves, Mamot, Christoph, Nayak, Lakshmi, Nag, Shona, Tran, David D, Recht, Lawrence D, Goldlust, Samuel A, O'Rourke, Donald M, Hamilton, Mark G, Wick, Wolfgang, Green, Jennifer, He, Yi, Turner, Christopher D, Yellin, Michael J, Keler, Tibor, Davis, Thomas A, Stupp, Roger, Sampson, John H

Publikováno v: In The Lancet Oncology October 2017 18(10):1373-1385

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

NRG/RTOG 0837: Randomized, phase II, double-blind, placebo-controlled trial of chemoradiation with or without cediranib in newly diagnosed glioblastoma.

Autor: Batchelor, Tracy T, Won, Minhee, Chakravarti, Arnab, Hadjipanayis, Costas G, Shi, Wenyin, Ashby, Lynn S, Stieber, Volker W, Robins, H Ian, Gray, Heidi J, Voloschin, Alfredo, Fiveash, John B, Robinson, Clifford G, Chamarthy, UshaSree, Kwok, Young, Cescon, Terrence P, Sharma, Anand K, Chaudhary, Rekha, Polley, Mei-Yin, Mehta, Minesh P

Publikováno v: Neuro-Oncology Advances; 2023, Vol. 5 Issue 1, p1-10, 10p

Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial

Autor: Reardon, David A, Desjardins, Annick, Vredenburgh, James J, O'Rourke, Donald M, Tran, David D, Fink, Karen L, Nabors, Louis B, Li, Gordon, Bota, Daniela A, Lukas, Rimas V, Ashby, Lynn S, Duic, J Paul, Mrugala, Maciej M, Cruickshank, Scott, Vitale, Laura, He, Yi, Green, Jennifer A, Yellin, Michael J, Turner, Christopher D, Keler, Tibor, Davis, Thomas A, Sampson, John H, ReACT trial investigators

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research, vol 26, iss 7

PurposeRindopepimut is a vaccine targeting the tumor-specific EGF driver mutation, EGFRvIII. The ReACT study investigated whether the addition of rindopepimut to standard bevacizumab improved outcome for patients with relapsed, EGFRvIII-positive glio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::c93fcdccbc6d12a3fdafdb40a3c42f4f
https://escholarship.org/uc/item/1pn1s022